Leishmaniasis worldwide and global estimates of its incidence, PLoS One, vol.7, 2012. ,
A phase II study to evaluate the safety and efficacy of topical 3 % amphotericin B cream ( Anfoleish ) for the treatment of uncomplicated cutaneous leishmaniasis in, PLoS Neglected Trop. Dis, vol.13, pp.1-12, 2018. ,
Evaluation of hypersensitivity to microencapsulated ampicillin in Guinea pigs, J. Antimicrob. Chemother, vol.39, pp.63-69, 1997. ,
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis, N. Engl. J. Med, vol.368, pp.524-532, 2013. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00793585
Drug permeation and barrier damage in Leishmania-infected mouse skin, J. Antimicrob. Chemother, vol.71, pp.1578-1585, 2016. ,
Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid, Biomaterials, vol.32, pp.8029-8039, 2011. ,
Treatment session: pooled analysis of Data from the phase 3 REFINE trials, Aesthet. Surg. J, vol.38, pp.998-1010, 2018. ,
DNDi's Strategy for Cutaneous Leishmaniasis, 2017. ,
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis, Int. J. Dermatol, vol.51, pp.1221-1225, 2012. ,
The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles, Int. J. Nanomed, vol.7, pp.5577-5591, 2012. ,
The mouse ear swelling test (MEST) in the 1990s, Toxicology, vol.93, pp.33-46, 1994. ,
Nanoparticles for drug delivery: the need for precision in reporting particle size parameters, Eur. J. Pharm. Biopharm, vol.69, pp.1-9, 2008. ,
Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis, Indian J. Dermatol, vol.59, pp.631-636, 2014. ,
Imaging of human cells exposed to an antifungal antibiotic amphotericin B reveals the mechanisms associated with the drug toxicity and cell defence, Sci. Rep. 1, 2018. ,
Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone ®, Pharm. Res. (N. Y.), vol.26, pp.1324-1331, 2009. ,
New world and old world Leishmania infections: a practical review, Dermatol. Clin, vol.33, pp.579-593, 2015. ,
Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line, J. Antimicrob. Chemother, vol.37, pp.519-533, 1996. ,
A simple method for quantifying Leishmania in tissues of infected animals, Parasitol. Today Off, vol.13, pp.40010-40012, 1997. ,
Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis, Trials, vol.13, pp.1-7, 2012. ,
Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier, Polymers, vol.3, pp.1377-1397, 2011. ,
A Review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis, PLoS Neglected Trop. Dis, vol.9, pp.1-23, 2015. ,
Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis, Exp. Parasitol, vol.186, pp.24-35, 2018. ,
Clinical Response with intralesional Amphotericin B in the treatment of old world cutaneous leishmaniasis : a preliminary report, Dermatol. Ther, vol.29, pp.398-405, 2016. ,
A simple practice guide for dose conversion between animals and human, J. Basic Clin. Pharm, vol.7, pp.27-31, 2016. ,
Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs . localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala, Am. J. Trop. Med. Hyg, vol.42, pp.43-50, 1990. ,
The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response, Int. Immunopharmacol, vol.11, pp.1557-1563, 2011. ,
CCl4-induced acute liver injury in mice is inhibited by hepatocyte growth factor overexpression but stimulated by NK2 overexpression, FEBS Lett, vol.532, pp.3714-3720, 2002. ,
Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis : a retrospective review of a Brazilian referral centre, Mem. Inst. Oswaldo Cruz, vol.111, pp.512-516, 2016. ,
Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama, Am. J. Trop. Med. Hyg, vol.89, pp.557-563, 2013. ,
Improved drug loading via spray drying of a chalcone implant for local treatment of cutaneous leishmaniasis, Drug Dev. Ind. Pharm, vol.18, pp.1-8, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01984692
Depot subcutaneous injection with chalcone CH8-loaded poly (Lactic-Co-Glycolic Acid) microspheres as a single-dose treatment of cutaneous leishmaniasis, Antimicrob. Agents Chemother, vol.62, pp.1822-1839, 2018. ,
Chemotherapy of leishmaniasis: present challenges, Parasitology, vol.20, pp.1-17, 2017. ,
Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani -infected primary macrophages, J. Antimicrob. Chemother, vol.73, pp.1314-1323, 2018. ,
FDA's Regulatory Science Program for Generic PLA/ PLGA -Based Drug Products, 2016. ,
, /Featured-Articles/188841-FDA-s-Regulatory-Science-Program-for-Generic-PLA-PLGA-Based-Drug-Products, Am. Pharm. Rev, 2016.
Local skin inflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B, Antimicrob. Agents Chemother, vol.62, pp.631-649, 2018. ,
Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome ® and AmBisome ® in murine cutaneous leishmaniasis, IJP Drugs Drug Resist, vol.8, pp.223-228, 2018. ,
AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy, Antimicrob. Agents Chemother, vol.62, pp.2009-02017, 2018. ,
In vitro and in vivo evaluations of PLGA microspheres containing nalmefene, PLoS One, vol.10, pp.1-19, 2015. ,
Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis, Antimicrob. Agents Chemother, vol.41, pp.752-756, 1997. ,